ArticleBMC pulmonary medicine2026
Prognostic and immunological roles of ammonia-induced cell death-related genes in non-small cell lung cancer.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLung cancer remains the predominant cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) comprising approximately 85% of cases, despite advancements in immunotherapy. This challenge is primarily due to the persistent dysfunction of effector T cells within the tumor microenvironment (TME). Ammonia-induced cell death (AICD), a newly identified form of programmed cell death, leads to the attrition of CD8⁺ T cells and contributes to immune suppression. However, the clinical significance of AICD in NSCLC has yet to be elucidated. In light of this context, the current study seeks to investigate AICD-related genes and their prognostic and immunological implications in NSCLC.
methodsTranscriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts were integrated with single-cell RNA sequencing and functional assays. Glutamine metabolism–related genes were retrieved from GeneCards and intersected with NSCLC differentially expressed genes to identify candidate AICD regulators. Prognostic value was evaluated by Kaplan–Meier survival and ROC analyses. Single-cell and immune infiltration analyses were used to define gene expression across malignant and immune subsets. Finally, Jurkat T cells were exposed to ammonia stress to validate gene function in AICD.
resultsFour genes—SLC7A5, SLC2A1, CAV1, and SPP1—emerged as key regulators of AICD in NSCLC. These genes were aberrantly expressed in tumors, stratified patient survival, and correlated with immune checkpoint activity and TME immunosuppression. A gene signature derived from the four regulators effectively predicted overall survival and immune response. Single-cell analysis confirmed their distribution across malignant and immune subpopulations. Functional assays demonstrated that CAV1, SPP1, and SLC7A5 protected against ammonia-induced T cell death, whereas SLC2A1 increased susceptibility.
conclusionThis study establishes AICD as a clinically relevant metabolic cell death mechanism in NSCLC and identifies SLC7A5, SLC2A1, CAV1, and SPP1 as potential prognostic biomarkers and therapeutic targets. Targeting ammonia metabolism may offer new strategies to overcome immune resistance and enhance immunotherapy efficacy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.